AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced the results of its DEFINE-HT clinical trial in heart ...

First patient enrolled in global randomized controlled trial with up to 3,200 participants at 100 sites comparing patient outcomes after percutaneous coronary intervention (PCI) procedures guided by ...

An independent data analysis center performed all statistical analyses, and the study sponsor and steering committee were blinded to individual treatment-level data until study completion. DEFINE was ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Researchers today presented results from the Phase III DEFINE (Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib) study with ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Researchers today presented results from the Phase III DEFINE (Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib) study with ...